BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Biofuel
,
Doxorubicin
,
rs3825942
,
TGFB1
,
calcium channel activity
,
Ischemia
,
Breast
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PARP%201
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for PARP%201
Explore Curated Studies Results
Literature
Most Relevant Literature
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in tripl…
First-in-Class NADH/Ubiquinone Oxidoreductase Core Subunit S7 (NDUFS7) Antagonist for the Treatment …
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagno…
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatmen…
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With P…
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With P…
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced S…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ